These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 9001979)
1. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. Reed JA; McNutt NS; Bogdany JK; Albino AP J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Reed JA; McNutt NS; Albino AP Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116 [TBL] [Abstract][Full Text] [Related]
3. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. Khare VK; Albino AP; Reed JA J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Tóth-Jakatics R; Jimi S; Takebayashi S; Kawamoto N Hum Pathol; 2000 Aug; 31(8):955-60. PubMed ID: 10987256 [TBL] [Abstract][Full Text] [Related]
6. The correlation of TRPM1 (Melastatin) mRNA expression with microphthalmia-associated transcription factor (MITF) and other melanogenesis-related proteins in normal and pathological skin, hair follicles and melanocytic nevi. Lu S; Slominski A; Yang SE; Sheehan C; Ross J; Carlson JA J Cutan Pathol; 2010 Apr; 37 Suppl 1(Suppl 1):26-40. PubMed ID: 20482673 [TBL] [Abstract][Full Text] [Related]
8. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression. Krengel S; Grotelüschen F; Bartsch S; Tronnier M J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278 [TBL] [Abstract][Full Text] [Related]
9. Mast cells in melanocytic skin lesions. An immunohistochemical and quantitative study. Dyduch G; Okoń K; Pescarini E Pol J Pathol; 2011 Sep; 62(3):139-44. PubMed ID: 22102069 [TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 in the tumor microenvironment correlates with melanoma invasion. Chiriboga L; Meehan S; Osman I; Glick M; de la Cruz G; Howell BS; Friedman-Jiménez G; Schneider RJ; Jamal S Melanoma Res; 2016 Jun; 26(3):236-44. PubMed ID: 26825037 [TBL] [Abstract][Full Text] [Related]
11. Mast cells in cutaneous tumors: innocent bystander or maestro conductor? Biswas A; Richards JE; Massaro J; Mahalingam M Int J Dermatol; 2014 Jul; 53(7):806-11. PubMed ID: 23621615 [TBL] [Abstract][Full Text] [Related]
12. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness. Kunz M; Hartmann A; Flory E; Toksoy A; Koczan D; Thiesen HJ; Mukaida N; Neumann M; Rapp UR; Bröcker EB; Gillitzer R Am J Pathol; 1999 Sep; 155(3):753-63. PubMed ID: 10487833 [TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 expression in melanocytic lesions of the skin. Ramirez JA; Guitart J; Rao MS; Diaz LK Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449 [TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556 [TBL] [Abstract][Full Text] [Related]
15. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours. Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788 [TBL] [Abstract][Full Text] [Related]
16. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977 [TBL] [Abstract][Full Text] [Related]
17. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. Schmid P; Itin P; Rufli T Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Sparrow LE; Heenan PJ Australas J Dermatol; 1999 Feb; 40(1):19-24. PubMed ID: 10098284 [TBL] [Abstract][Full Text] [Related]
19. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543 [TBL] [Abstract][Full Text] [Related]
20. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]